Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia (Dapan-Dia)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06047262 |
Recruitment Status :
Not yet recruiting
First Posted : September 21, 2023
Last Update Posted : April 24, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Mellitus, Type 2 | Drug: Dapansutrile Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | randomised controlled trial |
Masking: | Double (Participant, Investigator) |
Masking Description: | double-blind |
Primary Purpose: | Treatment |
Official Title: | A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With Type 2 Diabetes Mellitus |
Estimated Study Start Date : | May 2024 |
Estimated Primary Completion Date : | June 2026 |
Estimated Study Completion Date : | June 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Intervention Group
1000 mg dapansutrile (2 × 500mg tablets) administered twice a day from day 1 through the week 26 visit, inclusive. All tablets will be self-administered by mouth with water, with or without food.
|
Drug: Dapansutrile
Patients receive investigational product.
Other Names:
|
Placebo Comparator: Control Group
Matching placebo (2 tablets) administered twice a day from day 1 through the Week 26 visit, inclusive. All tablets will be self-administered by mouth with water, with or without food.
|
Drug: Placebo
Patients receive placebo. |
- Change in HbA1c in blood of patients for dapansutrile compared to placebo [ Time Frame: two time assessment at baseline and week 26 ]Comparison of change in HbA1c for dapansutrile and placebo
- Change in HbA1c in blood of patients for dapansutrile compared to placebo [ Time Frame: six time assessment at baseline and week 4, 8, 12, 16, 20 ]Comparison of change in HbA1c for dapansutrile and placebo
- Change in fasting plasma glucose for dapansutrile compared to placebo [ Time Frame: seven time assessement at baseline and week 4, 8, 12, 16, 20, 26 ]Comparison of change in fasting plasma glucose for dapansutrile and placebo
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of type 2, Diabetes mellitus as defined by the criteria of the American Diabetes Association (ADA) Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (see Appendix 1) and recognized by the World Health Organization (WHO, 2019), for at least 3 months prior to the Baseline Visit/Day 1
- HbA1c value of ≥ 7.7% to ≤ 11.0% at the Screening Visit.
- High-sensitivity C-reactive protein (hsCRP) ≥ 1.5 mg/L at the Screening Visit.
- Body mass index (BMI) ≥18 to ≤ 40 kg/m2 at the Screening Visit
- Acceptable overall medical condition to safely participate in the study and complete all study procedures (particularly with regard to cardiovascular, renal, and hepatic conditions), in the opinion of the Investigator
Exclusion Criteria:
- Diagnosis of type 1 diabetes mellitus
- HbA1c value of ≤ 7.5% or ≥ 10.5% at the Baseline Visit/Day 1, as determined at point of care (local laboratory)
- Use of thiazolidinediones (glitazones), pramlintide, or short-acting insulin/insulin analogues (as bolus or premixed insulin) within 12 weeks prior to the Screening Visit
- Less than 80% compliance in taking investigational medicinal product by pill count during the Run-In Period, as assessed at the Baseline Visit/Day 1
- Significant weight loss (> 5 kg) in the 12 weeks prior to the Screening Visit
- Systolic blood pressure (BP) ≥ 160 mmHg, diastolic BP ≥ 100 mmHg, or resting heart rate (HR) ≥ 100 beats/minute at the Screening Visit
- Previous myocardial infarction, any cardiac surgery
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06047262
Contact: Marc Y. Donath, Prof. | +41 61 265 50 78 | Marc.Donath@usb.ch | |
Contact: Matthias Hepprich, Dr. | +41 61 265 50 78 | matthias.hepprich@usb.ch |
Switzerland | |
University Hospital Basel | |
Basel, Switzerland, 4031 | |
Contact: Marc Y. Donath, Prof. +41 61 265 5078 marc.donath@usb.ch | |
Contact: Matthias Hepprich, Dr. +41 61 265 50 78 matthias.hepprich@usb.ch | |
Principal Investigator: Marc Y. Donath, Prof. |
Principal Investigator: | Marc Y. Donath, Prof. | University Hospital, Basel, Switzerland |
Responsible Party: | University Hospital, Basel, Switzerland |
ClinicalTrials.gov Identifier: | NCT06047262 |
Other Study ID Numbers: |
2023-01387; kt23Donath |
First Posted: | September 21, 2023 Key Record Dates |
Last Update Posted: | April 24, 2024 |
Last Verified: | April 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Dapansutrile Anti-Inflammatory Agents |